Multi-year license revenue timing
Revenue is recognized upfront for multi-year contracts, creating volatility between periods.
- Scope
- Qlucore Omics Explorer and Qlucore Insights
- Materiality
- high
Qlucore
Qlucore is a Swedish software company that develops AI-based tools for precision medicine and genetic data analysis. Its portfolio includes Qlucore Omics Explorer for research and Qlucore Diagnostics for clinical use, with customers in healthcare, research, and life sciences across Europe and other international markets.
| % | |
|---|---|
| Research software | 65% Software for advanced analysis and visualization of genetic and omics data. |
| Clinical diagnostics | 25% Regulatory-approved software tests used to support cancer diagnosis in healthcare. |
| Diagnostic development projects | 10% New cancer diagnostic models and tests under development with partners and grants. |
Qlucore sells to hospitals, clinical laboratories, and healthcare providers that use its diagnostic software to...
- Hospitals and healthcare systemsprimary
Buy diagnostic software for leukemia and other cancer applications to support clinical decision-making.
- Research institutionsprimary
Use Qlucore Omics Explorer for exploratory analysis of genetic and omics data.
- Pharmaceutical companiessecondary
Use the research platform for biomarker discovery and patient stratification.
- Clinical laboratoriessecondary
Adopt CE-marked diagnostic tests for regulated use in healthcare settings.
Qlucore is headquartered in Sweden and sells primarily into Europe, where CE-marking under IVDR is required for...
- •Sweden is the operating base and reporting currency is SEK
- •Europe is the core market for CE-marked diagnostics
- •United States is an important research and diagnostics market
- •China is served through an agent for software products
- •Middle East and other international markets add growth potential
Qlucore’s strategy is to expand from research software into regulated diagnostics by building a portfolio of CE-marked...
01
Build a broader diagnostics portfoliomedium-term
Multiple approved tests can increase clinical adoption and reduce dependence on one indication.
02
Expand commercial reach through partnersshort-term
Agents and distributors help scale sales in markets where direct coverage is limited.
03
Protect the research software franchiseshort-term
Omics Explorer remains the installed base and brand anchor for the company.
Qlucore depends on a small number of software products and on customer adoption in regulated healthcare markets, so...
Regulatory and clinical adoption risk
Diagnostics require CE marking and hospital acceptance before meaningful scale is achieved.
- Scope
- Qlucore Diagnostics
- Materiality
- high
Competition from free/open-source tools
Researchers may substitute lower-cost alternatives, reducing conversion and renewal rates.
- Scope
- Research software segment
- Materiality
- high
Dependence on research funding
Cuts in academic or public research budgets can delay purchases and renewals.
- Scope
- Research customers in Europe and the U.S.
- Materiality
- medium
Geopolitical and macroeconomic uncertainty
International sales and customer budgets can be affected by weaker global conditions.
- Scope
- China, U.S., and broader international markets
- Materiality
- medium
Multi-year license revenue recognition
Qlucore Omics Explorer and Qlucore Insights
Capitalized development costs
Clinical test development programs
Deferred tax asset recognition
Parent company tax deficit
Impairment of intangible assets
Software and development assets
: 11/08/2026